of ␣-synuclein. As shown in Figure 2A , the fibrillation of ␣-synuclein is completely inhibited by 100 M rifampicin as monitored by ThT. Confirmation that fibrillation was inhibited by rifampicin was obtained by static light scattering experiments (data not shown) and by measuring the amount of insoluble material as a function of time using the Lowry assay to determine the concentration of protein in both supernatant and pellet ( Figure 2B ) (aliquots were removed at various times during the incubation and centrifuged, prior to the assays). In addition, pellets and supernatants were analyzed using SDS PAGE: the data (data not shown) indicate that most of the protein (Ն90%) was in the insoluble fraction in the control experiment, whereas in the presence of rifampicin most of the protein was in the soluble fraction, confirming that rifampicin inhibited aggregation. Figures 2B desired time points and spun at 14,000 ϫ g for 15 min to remove insoluble material, and the supernatants were subjected to far-UV CD analysis. Figure 3A shows that the vicinity of 198 nm and the absence of bands in the 210-230 nm region. However, the far-UV CD spectrum within the time interval from 0 and 24 hr in the absence of rifampicin the far-UV CD spectrum of the soluble measured for the soluble fraction of ␣-synuclein after 40 hr of incubation possessed features characteristic of ␣-synuclein fraction was indicative of a substantially unfolded protein. This was manifested by a minimum in a partially folded conformation. Figure 3A shows that Figure 4A compares size-exclusion chromatography (SEC) profiles measured for the soluble fractions of ␣-synuclein incubated in the absence or presence of 100 M rifampicin. The position of the monomer peak (V el ϭ 18.5 ml, which corresponded to R S ϭ 35 Ϯ 2 Å , a value appropriate for natively unfolded ␣-synuclein [33]) was identical in the presence or absence of rifampicin. After 42 hr of incubation in the absence of rifampicin, there was only a trace of monomer present in the supernatant, whereas in the presence of 100 M rifampicin a large amount of monomer and some oligomer were observed in the solution. Thus, either a mixture of monomer and oligomer are formed in the presence of rifampicin, or the soluble oligomer(s) is not very stable and mostly dissociated during the chromatographic process. Regardless, the fact that the oligomers are present in the HPLC eluant after 15 min on the column indicates that the dissociation rate of the oligomers is quite slow. In either case, the results indicate that rifampicin prevents ␣-synuclein from fibrillation and deposition.
The HPLC SEC data provide a number of additional insights into the interaction of rifampicin with ␣-synuclein. As shown in Figure 4B , monitoring the absorbance at 480 nm, where only rifampicin absorbs, shows that the soluble material after 24 or 48 hr of incubation contains both monomeric and oligomeric ␣-synuclein and that, in both cases, rifampicin is tightly or covalently bound to the protein.
Further confirmation that rifampicin inhibits ␣-synuclein fibrillation comes from electron microscope (EM) . Under the conditions used ␣-synuclein showed a far-UV CD spectrum typical of a ␤ sheet protein, which we attribute to the presence of for ␣-synuclein fibrillation (pH 7.5, 37ЊC), we found the rate of degradation of 100 M rifampicin to be biphasic, soluble oligomeric intermediates of ␣-synuclein. It is important to note that because the CD spectra are only i.e., biexponential, with observed rate constants of 0.84 Ϯ 0.06 and 0.067 Ϯ 0.007 hr Ϫ1 , based on the deof the soluble fractions of the reaction mixture, the actual intensities of the far-UV CD spectra were decreased crease in absorbance at 483 nm. Thus, significant amounts of degradation products will be present during starting from 46 hr, when significant fibrillation began. In contrast, incubation of ␣-synuclein with rifampicin the incubation. This was confirmed by ESI mass spectrometry; the major component having a molecular mass (100 M) for 46 hr was not accompanied by any significant changes in the CD spectra ( Figure 3B ), indicating of 221.7 Da, corresponding to the naphthyl core of rifampicin. Other major products had molecular masses of the lack of change in the protein secondary structure. Only after incubation for 64 hr were minor changes in 353, 383 (quinone), 441, 455, and 528 Da. In order to determine whether rifampicin itself or its degradation the far-UV CD spectrum observed, and the intensities of the spectra did not decrease after incubation for 64 products were responsible for the inhibition of ␣-synuclein fibrillation, we preincubated 100 M rifampicin for hr in the presence of the rifampicin. 24 or 48 hr prior to initiating fibrillation. As shown in dation of rifampicin in the presence of oxygen (under nonanaerobic conditions), there will always be some Figure 6A , under anaerobic conditions, in which the oxidative breakdown of rifampicin is inhibited, the inhibitory oxidative products present, and these will increase at longer incubation times. Interestingly, in the presence effect of rifampicin was much reduced, indicating that it is one of the oxidative products that is responsible of antioxidants such as glutathione and ascorbic acid, which would be anticipated to minimize the oxidation for most of the inhibition. Given the relatively fast degra- of rifampicin, the addition of rifampicin to ␣-synuclein crease. This is most readily explained by assuming that some oxidation of rifampicin occurred, but at a slow rate, incubations led to minimal inhibition ( Figure 6B ). We interpret this to mean that the antioxidants resulted in and the resulting oxidized rifampicin inhibited further fibrillation and disaggregated existing fibrils (see below). maintenance of a high concentration of nonoxidized rifampicin, and this had little inhibitory effect. At longer ESI mass spectrometry was used to examine ␣-synuclein after incubation in the presence and absence of time periods of incubation with both rifampicin and glutathione or ascorbic acid, the ThT signal began to derifampicin: no detectable differences were observed, suggesting that the soluble ␣-synuclein (monomer and oligomers) had not been covalently modified by rifampicin or its degradation products, at least under the experimental conditions used. However, if a covalent imine adduct had formed between oxidized rifampicin and the lysine side chains of ␣-synuclein, it is possible that it would have been hydrolyzed under the acidic conditions used for preparing the MS sample.
Rifampicin Dissolves ␣-Synuclein Fibrils
We next addressed the question of whether rifampicin could disaggregate existing fibrils of ␣-synuclein. Figure  6C shows that coincubation of ␣-synuclein fibrils with 100 M rifampicin is accompanied by a large decrease in ThT signal as well as a substantial decrease in the Figures 5C and 5D) . protofibrils) present during aggregation may be more cytoWe used circular dichroism to investigate the secondtoxic then fibrils themselves [37-43]. The minimum kiary structure of ␣-synuclein in the soluble oligomers netic scheme for ␣-synuclein aggregation/fibrillation informed after disaggregation in the presence of rifampivolves the initial formation of a critical partially folded cin. Figure 7 compares the far-UV CD spectra of natively intermediate that undergoes partitioning either to fibrils, unfolded ␣-synuclein and the soluble fractions extracted soluble oligomers, or amorphous aggregates. from incubation of ␣-synuclein fibrils in the absence or
The data presented here indicate that rifampicin, in in the presence of rifampicin. Both spectra correspondthe 1-10 M concentration range, leads to inhibition ing to the soluble fractions had shapes typical of ␤-strucof ␣-synuclein fibril formation. Furthermore, the results tural proteins. The CD analysis clearly demonstrates that demonstrate that existing fibrils are disaggregated by the conformation of ␣-synuclein in the soluble species similar concentrations of rifampicin. In both cases, inhiresulting from rifampicin-induced dissociation of fibrils bition and disaggregation, the end product is a mixture was predominantly ␤-structure. Consequently, the SEC of a large soluble oligomer of ␣-synuclein, with substan-HPLC and far-UV CD data indicate that the rifampicintial ␤ sheet structure, and monomer. In addition, our disaggregated fibrils were stabilized in the form of large observations reveal that an oxidized form (or forms) of rifampicin is more potent than the parent compound soluble oligomers enriched in ␤-structure. 
